S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
His system isolated NVIDIA - Here's His Next Buy. (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
His system isolated NVIDIA - Here's His Next Buy. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
4 Proven Strategies to Help You Find Success in Executive Leadership
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
His system isolated NVIDIA - Here's His Next Buy. (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
His system isolated NVIDIA - Here's His Next Buy. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
4 Proven Strategies to Help You Find Success in Executive Leadership
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
His system isolated NVIDIA - Here's His Next Buy. (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
His system isolated NVIDIA - Here's His Next Buy. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
4 Proven Strategies to Help You Find Success in Executive Leadership
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
His system isolated NVIDIA - Here's His Next Buy. (Ad)
CarMax Slides On Earnings Disappointment, Time To Celebrate?
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
His system isolated NVIDIA - Here's His Next Buy. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
4 Proven Strategies to Help You Find Success in Executive Leadership
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
OTCMKTS:SKYE

Skye Bioscience (SKYE) Stock Forecast, Price & News

$4.09
+0.63 (+18.21%)
(As of 09/29/2023 ET)
Compare
Today's Range
$3.90
▼
$4.09
50-Day Range
$0.01
▼
$3.55
52-Week Range
$2.11
▼
$10.00
Volume
4,288 shs
Average Volume
2.53 million shs
Market Capitalization
$3.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest

SKYE stock logo

About Skye Bioscience (OTCMKTS:SKYE) Stock

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

SKYE Price History

SKYE Stock News Headlines

September 27, 2023 | finance.yahoo.com
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
September 5, 2023 | finance.yahoo.com
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 30, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
August 14, 2023 | finance.yahoo.com
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
July 13, 2023 | finance.yahoo.com
Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
July 6, 2023 | msn.com
Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
June 9, 2023 | travel.usnews.com
Isle of Skye
June 5, 2023 | finance.yahoo.com
Skye Bioscience to Present at LD Micro Invitational XIII
September 30, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
May 15, 2023 | finance.yahoo.com
Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
April 29, 2023 | finance.yahoo.com
Skye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo Finance
April 27, 2023 | finance.yahoo.com
Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist
April 19, 2023 | msn.com
Short Volatility Alert: Skye Bioscience
April 4, 2023 | finanznachrichten.de
Skye Bioscience, Inc.: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
April 4, 2023 | finance.yahoo.com
Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
April 3, 2023 | finanznachrichten.de
Skye Bioscience, Inc.: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal
March 15, 2023 | msn.com
Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma
March 11, 2023 | benzinga.com
Skye Bioscience Stock (OTC:SKYE), Analyst Ratings, Price Targets, Predictions
March 7, 2023 | finance.yahoo.com
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
February 24, 2023 | benzinga.com
Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study
February 23, 2023 | proactiveinvestors.com
Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review
February 16, 2023 | finance.yahoo.com
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
February 13, 2023 | finance.yahoo.com
Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
February 2, 2023 | finanznachrichten.de
Skye Bioscience, Inc.: Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
February 2, 2023 | finance.yahoo.com
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
January 31, 2023 | proactiveinvestors.com
Skye Bioscience gets positive safety review of SBI-100 OE after phase 1 first cohort
January 27, 2023 | msn.com
Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
See More Headlines
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SKYE Company Calendar

Today
9/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SKYE
CUSIP
N/A
CIK
1516551
Web
skyebioscience.com
Phone
(858) 410-0266
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-453.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-409.00

Miscellaneous

Outstanding Shares
971,550,000
Free Float
956,005,000
Market Cap
$3.97 billion
Optionable
Not Optionable
Beta
0.62
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Punit S. Dhillon B.A. (Age 43)
    BA, Exec. Chairman, Pres, CEO & Sec.
    Comp: $733.08k
  • Ms. Kaitlyn Melanie Arsenault CPA (Age 36)
    Chief Financial Officer
    Comp: $455.89k
  • Dr. Christopher G. Twitty Ph.D. (Age 50)
    Chief Scientific Officer
  • Mr. Tu Diep M.Sc.
    Chief Devel. Officer

Key Competitors

View All Competitors













SKYE Stock - Frequently Asked Questions

How have SKYE shares performed in 2023?

Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 25,146.9% and is now trading at $4.09.
View the best growth stocks for 2023 here.

Are investors shorting Skye Bioscience?

Skye Bioscience saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 24,200 shares, a decline of 67.2% from the August 15th total of 73,800 shares. Based on an average daily volume of 6,559,700 shares, the short-interest ratio is presently 0.0 days.
View Skye Bioscience's Short Interest.

What is Skye Bioscience's stock symbol?

Skye Bioscience trades on the OTCMKTS under the ticker symbol "SKYE."

How do I buy shares of Skye Bioscience?

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Skye Bioscience's stock price today?

One share of SKYE stock can currently be purchased for approximately $4.09.

How much money does Skye Bioscience make?

Skye Bioscience (OTCMKTS:SKYE) has a market capitalization of $3.97 billion. The company earns $-19,480,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

How can I contact Skye Bioscience?

Skye Bioscience's mailing address is 5910 PACIFIC CENTER BLVD SUITE 320, SAN DIEGO CA, 92121. The official website for the company is skyebioscience.com. The company can be reached via phone at (858) 410-0266 or via email at invest@emeraldbio.life.

This page (OTCMKTS:SKYE) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -